Monsanto Signs Licensing Agreement

Monsanto said it reached a new global licensing agreement with Harvard and the Broad Institute of the Massachusetts Institute of Technology for the use of the new CRISPR-Cpf1 genome-editing technology in agriculture.

The method has potential to be a simpler and more precise tool for making targeted improvements in a cell’s DNA when compared to the older CRISPR-Cas9 system, the company said on Wednesday.

“Monsanto believes that genome-editing technologies, including the CRISPR-Cpf1 system, will continue to provide a powerful tool for its research in plant breeding and biotechnology, with the promise to unlock the full potential of its world-leading germplasm and genome libraries and contribute to the development of exciting new products,” it said.

Leave a Comment